drugset / Trial / NCT00465621

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00465621

Phase 2 Completed 150 enrolled Alcon Research
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension

Timeline

Start
2007-03
Primary completion
2007-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AL-37807 Unknown 0.05 % Other
Subject AL-37807 Unknown 0.1 % Other
Subject AL-37807 Unknown 0.2 % Other
Subject Latanoprost Small molecule